Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

Opinion | Tocilizumab in COVID-19 therapy: who benefits, and how? – the researchers suggest that maybe IL-6 inhibitors should be given only to patients with high IL-6.

23 Jul, 2021 | 10:51h | UTC

Tocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet

Related: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. AND M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. AND RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes AND Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. AND M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.

 


Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

22 Jul, 2021 | 11:16h | UTC

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant – New England Journal of Medicine

Commentaries: Study Finds Pfizer And AstraZeneca Vaccines Effective Against The Delta Variant — As Long As You Get Both Doses – Forbes AND Pfizer’s COVID-19 vaccine works very well against the Delta variant — but only after 2 doses – Insider

Related: [Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant. AND Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. AND Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.

 

Commentary on Twitter

 


COVID-19 antibodies persist at least nine months after infection – “98.8 percent of people infected in February/March showed detectable levels of antibodies in November”.

22 Jul, 2021 | 11:14h | UTC

News release: COVID-19 antibodies persist at least nine months after infection – Imperial College London

Original study: SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’ – Nature Communications

 


Guideline on the management of IgE-mediated food allergies.

22 Jul, 2021 | 10:34h | UTC

Update of the S2k guideline on the management of IgE-mediated food allergies – Allergologie Select

 


Experts recommend Covid jabs for some under-18s in UK – “advice is that 16 to 18-year-olds can be offered a Pfizer jab if they are in a priority group or live with someone who has a weakened immune system”.

20 Jul, 2021 | 10:15h | UTC

Commentaries: Experts recommend Covid jabs for some under-18s in UK – BBC

See report: JCVI statement on COVID-19 vaccination of children and young people aged 12 to 17 years: 15 July 2021 – Joint Committee on Vaccination and Immunisation

 


Position Paper: Recommendations for the use of topical inhalant budesonide in COVID-19.

18 Jul, 2021 | 23:53h | UTC

Recommendations for use of topical inhalant budesonide in COVID-19 – HNO

Related: RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19 AND Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19

 


Studies elucidate poorly understood long COVID.

18 Jul, 2021 | 23:42h | UTC

Studies elucidate poorly understood long COVID – CIDRAP

 


Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – “This study found a low prevalence of symptoms compatible with long COVID in a randomly selected cohort of children assessed 6 months after serologic testing”.

16 Jul, 2021 | 11:06h | UTC

Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents – JAMA

 


Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

16 Jul, 2021 | 11:02h | UTC

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination – New England Journal of Medicine

Related: [Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”. AND Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”. AND RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Commentary on Twitter

 


Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

16 Jul, 2021 | 11:00h | UTC

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination – Nature Medicine

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination – New England Journal of Medicine

Related: [Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”. AND Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”. AND RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Commentary on Twitter

 


RCT: Bamlanivimab plus Etesevimab reduce mortality and hospitalization in ambulatory patients with early Covid-19 (within 3 days of a positive test) who are at risk for clinical deterioration (i.e., older people, obese, diabetics, immunocompromised, with CV disease).

15 Jul, 2021 | 09:26h | UTC

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 – New England Journal of Medicine

 


Millions of children worldwide missed routine vaccinations during the pandemic, study suggests.

15 Jul, 2021 | 09:24h | UTC

Millions of children worldwide missed routine vaccinations during the pandemic, study suggests – CNN

Original study: Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study – The Lancet

Invited Commentary: Disruptions to childhood immunisation due to the COVID-19 pandemic – The Lancet

 


Long COVID and kids: scientists race to find answers – “Children get long COVID too, but researchers are still working to determine how frequently and how severely”.

15 Jul, 2021 | 09:23h | UTC

Long COVID and kids: scientists race to find answers – Nature

 


Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.

14 Jul, 2021 | 11:20h | UTC

Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women – JAMA

Commentary: Pfizer COVID vaccine shows 78% efficacy in pregnancy – CIDRAP

 


New Zealand children falling ill in high numbers due to Covid ‘immunity debt’.

14 Jul, 2021 | 11:16h | UTC

New Zealand children falling ill in high numbers due to Covid ‘immunity debt’ – The Guardian

Related: New Zealand, where Covid-19 is dormant, fights another respiratory virus – The New York Times


Long Covid: 39% of patients report persistent symptoms more than seven months after diagnosis of COVID-19 in an outpatient setting.

13 Jul, 2021 | 09:57h | UTC

Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-19 in an Outpatient Setting – Annals of Internal Medicine

Commentaries: Long COVID symptoms in a third of people with COVID-19 – American College of Physicians AND Covid-19: 1-in-3 Patients Reported Long-Hauler Symptoms – Physician’s Weekly

 

Commentary on Twitter

 


[Preprint] Long Covid: Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people.

13 Jul, 2021 | 09:55h | UTC

Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people – medRxiv

Commentary: Study explores the prevalence of long COVID in England – News Medical

 


WHO warns against mixing and matching COVID vaccines.

13 Jul, 2021 | 09:53h | UTC

WHO warns against mixing and matching COVID vaccines – Reuters

Commentary: WHO cautions data still limited on mixing COVID-19 vaccines, but Canadian officials say it’s OK – CTV News

Related: Germany issues world’s strongest recommendation for mixing Covid-19 vaccines. AND [Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”. AND Perspective | Can I get AstraZeneca now and Pfizer later? Why mixing and matching COVID vaccines could help solve many rollout problems. AND RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects. AND Should you mix and match COVID-19 vaccines? Scientists are seeking answers

 

Commentary on Twitter

 


Extremely rare cases of Guillain-Barré reported with Johnson & Johnson vaccine for Covid-19.

13 Jul, 2021 | 09:48h | UTC

J&J’s Covid-19 vaccine may trigger neurological condition in rare cases, FDA says – STAT

See also: Johnson & Johnson Vaccine Is Linked To Neurological Disorder In Extremely Rare Cases – NPR AND F.D.A. Attaches Warning of Rare Nerve Syndrome to Johnson & Johnson Vaccine – The New York Times

 


Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.

12 Jul, 2021 | 03:08h | UTC

Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast – CNN

See also: CDC, FDA contradict Pfizer on COVID-19 vaccine booster – CIDRAP AND Do I need a COVID-19 booster shot? 6 questions answered on how to stay protected – The Conversation AND Pfizer suggests booster shots will be needed this year, but government officials say science will dictate the timing – The Washington Post AND Pfizer to seek OK for 3rd vaccine dose; shots still protect – Associated Press AND Citing the Delta Variant, Pfizer Will Pursue Booster Shots and a New Vaccine – The New York Times (a few articles per month are free) AND Question open on need for COVID booster shot, data awaited, WHO says – Reuters

 


A correlate of protection for SARS-CoV-2 vaccines is urgently needed – “Recent studies suggest that neutralizing antibodies could serve as a correlate of protection for vaccines against SARS-CoV-2 in humans”.

12 Jul, 2021 | 03:03h | UTC

A correlate of protection for SARS-CoV-2 vaccines is urgently needed – Nature Medicine

Related: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

 


Prospective national cohort in Chile showed CoronaVac effectiveness was 65.9% for symptomatic Covid-19, 87.5% for hospitalization, 90.3% for ICU admission, and 86.3% for death.

8 Jul, 2021 | 09:22h | UTC

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile – New England Journal of Medicine

Related: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years. AND WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. AND Brazilian town experiment shows mass vaccination can wipe out COVID-19.

 

Commentary on Twitter

 


Case series: therapeutic plasma exchange in 3 patients with vaccine-induced immune thrombotic thrombocytopenia.

8 Jul, 2021 | 09:17h | UTC

Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia – New England Journal of Medicine

 

Commentary on Twitter

 


Mounting evidence suggests Sputnik COVID vaccine is safe and effective.

8 Jul, 2021 | 09:14h | UTC

Mounting evidence suggests Sputnik COVID vaccine is safe and effective – Nature

Related: Russia Pushes Ahead with Open License Approach to Sputnik V – Despite WHO Concerns Over Manufacturing Practices – Health Policy Watch

 


Perspective | Should People With Immune Problems Get Third Vaccine Doses?

8 Jul, 2021 | 09:07h | UTC

Should People With Immune Problems Get Third Vaccine Doses? – The New York Times (a few articles per month are free)

Related: [Preprint] 3rd AstraZeneca shot gives strong immunity. AND Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.

 


Stay Updated in Your Specialty

No spam, just news.